Clinical Trial Update: Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating aggressive induction therapy followed by autologous stem cell transplantation using denileukin diftitox (Ontak) for peripheral T-cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Denileukin diftitox (denileukin diftitox)

Snippet

Sponsor: University of California, San Francisco | Conditions: Peripheral T-Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2020-04-27